India is now the third country in the world to record more than 2 million coronavirus cases. The country is enduring a terrible surge in new cases — 62,538 were reported on Friday alone. Only the U.S. and Brazil are reporting more.
India passed 1 million confirmed cases just three weeks ago.
So far, India’s fatality rate from COVID-19 is relatively low, at just over 2%. Around 41,500 people have died from the disease — fewer than in the U.K., for instance, where more than 46,400 deaths have occurred, out of around 310,000 cases.
But India’s fatality statistics might be artificially low because only a small portion of deaths that occur in India — reportedly around 22%, as of last year — are medically certified.
In India’s outbreak, the western state of Maharashtra, where Mumbai is located, is the worst-hit, with around 480,000 cases reported. But the coronavirus has also infected hundreds of thousands of people in southern states such as Andhra Pradesh and Tamil Nadu.
“The virus has moved from megacities like Mumbai and Delhi to smaller towns and rural areas, where health care is already scant,” NPR’s Lauren Frayer reports. “Experts say it’s months away from hitting its peak.”
Despite reaching the daunting benchmark, it’s possible India’s cases are undercounted, due to the lack of widespread testing in one of the world’s largest and most populous countries. On Thursday, only 639,042 coronavirus tests were conducted in the country, according to India’s Ministry of Health and Family Welfare.
The U.S. has posted similar daily testing figures in the past month – but the U.S. population is far smaller, with 330 million people compared to India’s 1.3 billion.
As the world awaits a COVID-19 vaccine, a large vaccine maker in India announced on Friday that it will produce up to 100 million doses of a future vaccine and price each dose at $3 or less, for sales in India and to low- and middle-income countries.
The Serum Institute of India says its plan is supported by $150 million in funding from the Bill and Melinda Gates Foundation.
“The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax,” the company says.